• Disease areas
  • Science & technology
  • Partnering & innovation
  • Sustainable business
  • Careers
  • About us
  • Our products
  • Investors
  • News & media
  • Patient help
  • Healthcare professionals
  • Contact us

Investors

Share price

{{priceData.date}} {{priceData.time}}

{{priceData.currentPrice}} {{priceData.currency}}
Go to stock watch {{priceData.change}} {{priceData.currency}}

Quick links

Visit Capital Markets Day Stock information Press releases and company announcements R&D pipeline Upcoming events

Annual Report

Cover page of the Novo Nordisk Annual Report 2022

Annual Report 2022

Download Annual Report

Latest news

{{'2023-03-24T15:28:48Z' | dateFormatFilter}}

Oral semaglutide 25 mg and 50 mg demonstrate superior reductions in HbA1c and body weight versus 14 mg in people with type 2 diabetes in the PIONEER PLUS phase 3 trial

Read more

{{'2023-03-23T15:16:17Z' | dateFormatFilter}}

Resolutions from the Annual General Meeting of Novo Nordisk A/S

Read more

{{'2023-03-07T11:00:38Z' | dateFormatFilter}}

Novo Nordisk announces changes in Executive Management

Read more

News archive

Career Opportunities

Dear colleague

Please click here to go directly to our internal career site to view all our current job openings.

Here are our current job openings. If there is not a job you are looking for, you are welcome to create a job agent or a candidate profile.

 

 

 

NOVO NORDISK HQ

Novo Nordisk A/S
Novo Alle 1
2880 Bagsværd
Denmark
+45-4444-8888
CVR-no. 24256790

 

Our medicines are for the approved indication for which they are authorised in the local country or region. For more information, please visit our product page

Helpful links

Patient help Supplier help Product list Contact us Annual Report ESG reporting Novo Nordisk Foundation

Follow us

LinkedIn YouTube Facebook Twitter Instagram TikTok

Find your local office

Select location
© 2023 Novo Nordisk A/S Data Privacy Cookie policy Cookie settings

change